This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Comparison of streptokinase and alteplase

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

streptokinase

Alteplase (t-PA)

molecular weight (daltons)

47K

70K

fibrin specificity

minimal

moderate

plasminogen binding

indirect

direct

potential allergic reaction

yes

no

plasma clearance (mins)

15-25

4-8

relative cost

+

+++

A meta-analysis of eight comparisons of standard alteplase with streptokinase found no significant difference between the two drugs in terms of mortality up to 35 days (odds ratio 1.0; 95% CI 0.94 to 1.06). A statistically significant difference in reinfarction rates in favour of alteplase was found (odds ratio 0.86; 95% CI 0.77 to 0.95). However, alteplase was associated with a statistically significant higher risk of stroke (odds ratio 1.37; 95% CI 1.16 to 1.62), due to a doubling in the risk of haemorrhagic stroke (odds ratio 2.13; 95% CI 1.04 to 4.36). However, streptokinase was associated with a statistically significant higher risk of major bleeds (other than stroke) than alteplase (odds ratio 0.81; 95% CI 0.68 to 0.97). The categorisation and reporting of major bleeding varied between the trials and so it is difficult to judge the clinical significance of these findings.

Reference:

  1. NICE (October 2002). Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction.

 


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page